R & D

Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial

 This material is intended to notify the press release issued on May19 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.